CCI clears Berhyanda's acquisition of Suven Pharma

The acquisition is “by way of a share purchase agreement of December 26, 2022 and pursuant to the mandatory open offer in compliance with the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011”, the competition regulator said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qc5bDSZ
via IFTTT